Guidant General Surgery Divestiture To USSC Represents Sales Of $40 Mil.
This article was originally published in The Gray Sheet
Executive Summary
Guidant's general surgery business, which will be sold to Tyco Healthcare Group's U.S. Surgical division under an agreement announced July 7, generated annual revenues of about $40 mil., analysts estimate.
You may also be interested in...
GSI Sole Supplier of Balloon Dissection Devices Following Guidant Injunction
General Surgical Innovations says it will be the sole supplier of balloon dissection-based devices for minimally invasive surgery in the U.S. effective Nov. 15, the result of an April 14 injunction against rival Origin Medsystems, a subsidiary of Guidant.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.